FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:740-741 September 7, 2000 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

To the Editor: Capecitabine (Xeloda, Roche Laboratories) is an orally administered fluoropyrimidine carbamate used for the treatment of metastatic breast cancer and colon cancer.^1,2,3,4 We describe two patients in whom marked ocular irritation, decreased vision, and corneal deposits developed during chemotherapy with capecitabine.

Patient 1 was a 48-year-old woman with metastatic breast cancer, a history of keratoconjunctivitis sicca, and 20/20 visual acuity in each eye who had severe bilateral irritation and decreased vision after two cycles of capecitabine (4600 mg per day for 14 days and 3000 mg per day for 14 days). Her visual acuity decreased to 20/40 in . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Zarfoss, M., Bentley, E., Milovancev, M., Schmiedt, C., Dubielzig, R., McAnulty, J. (2007). Histopathologic Evidence of Capecitabine Corneal Toxicity in Dogs. Vet Pathol 44: 700-702 [Abstract] [Full Text]